Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.
Press releases published on August 11, 2025
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial …
Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week
GlobeNewswire
·
August 11, 2025
ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. …
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
GlobeNewswire
·
August 11, 2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private …
WeightWatchers Announces Second Quarter 2025 Results
GlobeNewswire
·
August 11, 2025
Successful completion of strategic reorganization, reducing debt by $1.15 billion. In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a “Successor” period from 6/25/25 to 6/30/25 Combined End …
BioCryst Announces Departure of Dr. Helen Thackray
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an …
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
GlobeNewswire
·
August 11, 2025
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumors …
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
August 11, 2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track …
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
GlobeNewswire
·
August 11, 2025
In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall …
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a …
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
GlobeNewswire
·
August 11, 2025
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with …
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GlobeNewswire
·
August 11, 2025
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial Phase 1 results …
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
GlobeNewswire
·
August 11, 2025
BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in …
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
GlobeNewswire
·
August 11, 2025
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 million CARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years Presented other …
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess™ - - ECAT approval makes Symvess available to 35 …
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
GlobeNewswire
·
August 11, 2025
Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025 All other clinical trials in previously announced six-indications …
Harvard Bioscience Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit Amendment Signed, Extending Refinance Deadline to …
Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas
GlobeNewswire
·
August 11, 2025
Houston Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its …
I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers
GlobeNewswire
·
August 11, 2025
Enrollment in the planned second dose expansion cohort completed ahead of expectations Topline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- I-Mab ( …
FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156
GlobeNewswire
·
August 11, 2025
• First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF PRUSSIA, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company …
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept trial of SION-719 as an add-on to …